TABLE OF CONTENTS
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF GLOBAL PEN NEEDLES MARKET 19
1.4 CURRENCY AND PRICING 20
1.5 LIMITATIONS 21
1.6 MARKETS COVERED 21
2 MARKET SEGMENTATION 23
2.1 MARKETS COVERED 23
2.2 GLOBAL PEN NEEDLES MARKET: GEOGRAPHICAL SCOPE 24
2.3 YEARS CONSIDERED FOR THE STUDY 25
2.4 DBMR TRIPOD DATA VALIDATION MODEL 26
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.6 DBMR MARKET POSITION GRID 30
2.7 MULTIVARIATE MODELING 31
2.8 PRODUCTS LIFELINE CURVE 31
2.9 VENDOR SHARE ANALYSIS 32
2.10 SECONDARY SOURCES 33
2.11 ASSUMPTIONS 33
3 MARKET OVERVIEW 34
3.1 DRIVERS 36
3.1.1 INCREASING PREVALENCE OF DIABETES 36
3.1.2 INCREASING GERIATRIC POPULATION 38
3.1.3 RISING GOVERNMENT INITIATIVES 40
3.2 RESTRAINT 41
3.2.1 PREFERENCE FOR ALTERNATIVE MODES OF DRUG DELIVERY 41
3.3 OPPORTUNITIES 42
3.3.1 RISE IN AWARENESS AMONG THE POPULATION 42
3.3.2 INCREASING BIOSIMILAR DRUG AVAILABILITY 43
3.4 CHALLENGES 44
3.4.1 REUSE OF PEN NEEDLES 44
3.4.2 STRICT REGULATORY REQUIREMENTS 45
?
4 EXECUTIVE SUMMARY 46
4.1 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL PEN NEEDLES MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026 48
5 PREMIUM INSIGHTS 49
6 GLOBAL PEN NEEDLES MARKET, BY PRODUCT TYPE 50
6.1 OVERVIEW 51
6.2 STANDARD PEN NEEDLES 52
6.3 SAFETY PEN NEEDLES 53
7 GLOBAL PEN NEEDLES MARKET, BY PRODUCT LENGTH 54
7.1 OVERVIEW 55
7.2 MEDIUM LENGTH 56
7.3 NANO LENGTH 57
7.4 LONG LENGTH 58
8 GLOBAL PEN NEEDLES MARKET, BY USABILITY 59
8.1 OVERVIEW 60
8.2 REUSABLE 61
8.3 DISPOSABLE 62
9 GLOBAL PEN NEEDLES MARKET, BY APPLICATION 63
9.1 OVERVIEW 64
9.2 DIABETES 65
9.3 GROWTH HORMONE DEFICIENCY 66
9.4 OTHERS 67
10 GLOBAL PEN NEEDLES MARKET, BY THERAPY 68
10.1 OVERVIEW 69
10.2 INSULIN 70
10.3 GLUCAGON-LIKE PEPTIDE-1 70
10.4 GROWTH HORMONES 71
10.5 OTHERS 72
11 GLOBAL PEN NEEDLES MARKET, BY END USER 73
11.1 OVERVIEW 74
11.2 HOME HEALTHCARE 75
11.3 HOSPITALS 76
11.4 CLINICS 77
11.5 OTHERS 78
12 GLOBAL PEN NEEDLES MARKET, BY GEOGRAPHY 79
12.1 OVERVIEW 80
12.2 NORTH AMERICA 85
12.2.1 U.S. 90
12.2.2 CANADA 92
12.2.3 MEXICO 94
12.3 EUROPE 96
12.3.1 GERMANY 101
12.3.2 FRANCE 103
12.3.3 ITALY 105
12.3.4 U.K. 107
12.3.5 SPAIN 109
12.3.6 RUSSIA 111
12.3.7 NETHERLANDS 113
12.3.8 SWITZERLAND 115
12.3.9 BELGIUM 117
12.3.10 TURKEY 119
12.3.11 REST OF EUROPE 121
12.4 ASIA-PACIFIC 122
12.4.1 CHINA 127
12.4.2 JAPAN 129
12.4.3 INDIA 131
12.4.4 SOUTH KOREA 133
12.4.5 AUSTRALIA 135
12.4.6 MALAYSIA 137
12.4.7 SINGAPORE 139
12.4.8 THAILAND 141
12.4.9 INDONESIA 143
12.4.10 PHILIPPINES 145
12.4.11 REST OF ASIA-PACIFIC 147
12.5 SOUTH AMERICA 148
12.5.1 BRAZIL 153
12.5.2 REST OF SOUTH AMERICA 155
12.6 MIDDLE EAST & AFRICA 156
12.6.1 SOUTH AFRICA 161
12.6.2 REST OF MIDDLE EAST & AFRICA 163
?
13 GLOBAL PEN NEEDLES MARKET, COMPANY LANDSCAPE 164
13.1 COMPANY SHARE ANALYSIS: GLOBAL 164
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 165
13.3 COMPANY SHARE ANALYSIS: EUROPE 166
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 167
14 COMPANY PROFILE 168
14.1 NOVO NORDISK A/S 168
14.1.1 COMPANY SNAPSHOT 168
14.1.2 REVENUE ANALYSIS 168
14.1.3 COMPANY SHARE ANALYSIS 169
14.1.4 PRODUCT PORTFOLIO 169
14.1.5 RECENT DEVELOPMENTS 170
14.2 SANOFI 171
14.2.1 COMPANY SNAPSHOT 171
14.2.2 REVENUE ANALYSIS 171
14.2.3 COMPANY SHARE ANALYSIS 172
14.2.4 PRODUCT PORTFOLIO 172
14.2.5 RECENT DEVELOPMENTS 172
14.3 ELI LILLY AND COMPANY 173
14.3.1 COMPANY SNAPSHOT 173
14.3.2 REVENUE ANALYSIS 173
14.3.3 COMPANY SHARE ANALYSIS 174
14.3.4 PRODUCT PORTFOLIO 174
14.3.5 RECENT DEVELOPMENTS 175
14.4 BD 176
14.4.1 COMPANY SNAPSHOT 176
14.4.2 REVENUE ANALYSIS 176
14.4.3 COMPANY SHARE ANALYSIS 177
14.4.4 PRODUCT PORTFOLIO 177
14.4.5 RECENT DEVELOPMENTS 178
14.5 A. MENARINI DIAGNOSTICS SRL 179
14.5.1 COMPANY SNAPSHOT 179
14.5.2 PRODUCT PORTFOLIO 179
14.5.3 RECENT DEVELOPMENT 180
14.6 ALLISON MEDICAL, INC. 181
14.6.1 COMPANY SNAPSHOT 181
14.6.2 PRODUCT PORTFOLIO 181
14.6.3 RECENT DEVELOPMENT 181
?
14.7 B. BRAUN MELSUNGEN AG 182
14.7.1 COMPANY SNAPSHOT 182
14.7.2 REVENUE ANALYSIS 182
14.7.3 PRODUCT PORTFOLIO 183
14.7.4 RECENT DEVELOPMENTS 183
14.8 DIGITAL MEDICS PTY LTD 184
14.8.1 COMPANY SNAPSHOT 184
14.8.2 PRODUCT PORTFOLIO 184
14.8.3 RECENT DEVELOPMENTS 184
14.9 DOMREX PHARMA INC. 185
14.9.1 COMPANY SNAPSHOT 185
14.9.2 PRODUCT PORTFOLIO 185
14.9.3 RECENT DEVELOPMENT 185
14.10 FACET MEDICAL TECHNOLOGIES 186
14.10.1 COMPANY SNAPSHOT 186
14.10.2 PRODUCT PORTFOLIO 186
14.10.3 RECENT DEVELOPMENT 186
14.11 HTL- STREFA S.A. 187
14.11.1 COMPANY SNAPSHOT 187
14.11.2 PRODUCT PORTFOLIO 187
14.11.3 RECENT DEVELOPMENTS 187
14.12 KD MEDICAL GMBH HOSPITAL PRODUCTS 188
14.12.1 COMPANY SNAPSHOT 188
14.12.2 PRODUCT PORTFOLIO 188
14.12.3 RECENT DEVELOPMENT 188
14.13 LDI LTD., LLC 189
14.13.1 COMPANY SNAPSHOT 189
14.13.2 PRODUCT PORTFOLIO 189
14.13.3 RECENT DEVELOPMENTS 189
14.14 MEDEXEL CO., LTD. 190
14.14.1 COMPANY SNAPSHOT 190
14.14.2 PRODUCT PORTFOLIO 190
14.14.3 RECENT DEVELOPMENT 191
14.15 OWEN MUMFORD LTD 192
14.15.1 COMPANY SNAPSHOT 192
14.15.2 PRODUCT PORTFOLIO 192
14.15.3 RECENT DEVELOPMENT 193
?
14.16 PENDIQ GMBH 194
14.16.1 COMPANY SNAPSHOT 194
14.16.2 PRODUCT PORTFOLIO 194
14.16.3 RECENT DEVELOPMENT 194
14.17 STAT MEDICAL DEVICES. 195
14.17.1 COMPANY SNAPSHOT 195
14.17.2 PRODUCT PORTFOLIO 195
14.17.3 RECENT DEVELOPMENT 195
14.18 TERUMO CORPORATION 196
14.18.1 COMPANY SNAPSHOT 196
14.18.2 REVENUE ANALYSIS 196
14.18.3 PRODUCT PORTFOLIO 197
14.18.4 RECENT DEVELOPMENTS 198
14.19 VOGT MEDICAL 199
14.19.1 COMPANY SNAPSHOT 199
14.19.2 PRODUCT PORTFOLIO 199
14.19.3 RECENT DEVELOPMENT 199
14.20 WILHELM HASELMEIER GMBH & CO. KG 200
14.20.1 COMPANY SNAPSHOT 200
14.20.2 PRODUCT PORTFOLIO 200
14.20.3 RECENT DEVELOPMENTS 201
14.21 YPSOMED AG 202
14.21.1 COMPANY SNAPSHOT 202
14.21.2 REVENUE ANALYSIS 202
14.21.3 PRODUCT PORTFOLIO 203
14.21.4 RECENT DEVELOPMENTS 204
15 QUESTIONNAIRE 205
16 RELATED REPORTS 209
?